Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3617696 | 0.91 | HDAC1 (0.57) | HDAC1HDAC3HDAC2HDAC10NCOR2 | |
| SCHEMBL4895682 | 0.88 | HDAC1 (0.58) | HDAC1HDAC3HDAC2HDAC10NCOR2 | |
| SCHEMBL4890641 | 0.81 | HDAC1 (0.67) | HDAC1HDAC3HDAC2HDAC10NCOR2 | |
| SCHEMBL4899345 | 0.80 | HDAC1 (0.57) | HDAC1HDAC3KCNH2 | |
| SCHEMBL4897235 | 0.78 | HDAC1 (0.71) | HDAC1HDAC3HDAC2HDAC10KCNH2 | |
| SCHEMBL4897259 | 0.77 | HDAC1 (0.69) | HDAC1HDAC2KCNH2 | |
| SCHEMBL4899338 | 0.76 | HDAC1 (0.63) | HDAC1HDAC3HDAC2HDAC10NCOR2 | |
| SCHEMBL8265319 | 0.76 | HDAC1 (0.59) | HDAC1HDAC3HDAC2HDAC10NCOR2 | |
| SCHEMBL4899357 | 0.76 | HDAC1 (0.70) | HDAC1HDAC3HDAC2HDAC10KCNH2 | |
| SCHEMBL3609062 | 0.76 | HDAC1 (0.57) | HDAC1HDAC3HDAC2HDAC10NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119451-A1 | Novel Benzamide Derivatives | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | US | claimed |
| US-20080119451-A1 | Novel Benzamide Derivatives | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119451-A1 | Novel Benzamide Derivatives | HDAC1, HDAC11, HDAC2 | HDAC1 1/4885HDAC3 5/4885HDAC2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.